全文获取类型
收费全文 | 34955篇 |
免费 | 2913篇 |
国内免费 | 892篇 |
专业分类
耳鼻咽喉 | 815篇 |
儿科学 | 679篇 |
妇产科学 | 490篇 |
基础医学 | 5978篇 |
口腔科学 | 878篇 |
临床医学 | 3349篇 |
内科学 | 6048篇 |
皮肤病学 | 392篇 |
神经病学 | 3266篇 |
特种医学 | 961篇 |
外国民族医学 | 5篇 |
外科学 | 3091篇 |
综合类 | 3173篇 |
一般理论 | 1篇 |
预防医学 | 2330篇 |
眼科学 | 480篇 |
药学 | 3498篇 |
12篇 | |
中国医学 | 949篇 |
肿瘤学 | 2365篇 |
出版年
2023年 | 682篇 |
2022年 | 884篇 |
2021年 | 1837篇 |
2020年 | 1659篇 |
2019年 | 1304篇 |
2018年 | 1304篇 |
2017年 | 1314篇 |
2016年 | 1241篇 |
2015年 | 1441篇 |
2014年 | 2146篇 |
2013年 | 2904篇 |
2012年 | 1782篇 |
2011年 | 1969篇 |
2010年 | 1564篇 |
2009年 | 1657篇 |
2008年 | 1606篇 |
2007年 | 1465篇 |
2006年 | 1349篇 |
2005年 | 1111篇 |
2004年 | 1007篇 |
2003年 | 879篇 |
2002年 | 755篇 |
2001年 | 622篇 |
2000年 | 492篇 |
1999年 | 461篇 |
1998年 | 370篇 |
1997年 | 366篇 |
1996年 | 281篇 |
1995年 | 343篇 |
1994年 | 313篇 |
1993年 | 256篇 |
1992年 | 273篇 |
1991年 | 271篇 |
1990年 | 208篇 |
1989年 | 201篇 |
1988年 | 174篇 |
1987年 | 178篇 |
1986年 | 179篇 |
1985年 | 268篇 |
1984年 | 264篇 |
1983年 | 163篇 |
1982年 | 226篇 |
1981年 | 158篇 |
1980年 | 148篇 |
1979年 | 152篇 |
1978年 | 86篇 |
1977年 | 74篇 |
1976年 | 78篇 |
1975年 | 48篇 |
1973年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):301-326
ObjectiveThe use of mechanical circulatory support (MCS) in lung transplantation has been steadily increasing over the prior decade, with evolving strategies for incorporating support in the preoperative, intraoperative, and postoperative settings. There is significant practice variability in the use of these techniques, however, and relatively limited data to help establish institutional protocols. The objective of the AATS Clinical Practice Standards Committee (CPSC) expert panel was to review the existing literature and establish recommendations about the use of MCS before, during, and after lung transplantation.MethodsThe AATS CPSC assembled an expert panel of 16 lung transplantation physicians who developed a consensus document of recommendations. The panel was broken into subgroups focused on preoperative, intraoperative, and postoperative support, and each subgroup performed a focused literature review. These subgroups formulated recommendation statements for each subtopic, which were evaluated by the entire group. The statements were then developed via discussion among the panel and refined until consensus was achieved on each statement.ResultsThe expert panel achieved consensus on 36 recommendations for how and when to use MCS in lung transplantation. These recommendations included the use of veno-venous extracorporeal membrane oxygenation (ECMO) as a bridging strategy in the preoperative setting, a preference for central veno-arterial ECMO over traditional cardiopulmonary bypass during the transplantation procedure, and the benefit of supporting selected patients with MCS postoperatively.ConclusionsAchieving optimal results in lung transplantation requires the use of a wide range of strategies. MCS provides an important mechanism for helping these critically ill patients through the peritransplantation period. Despite the complex nature of the decision making process in the treatment of these patients, the expert panel was able to achieve consensus on 36 recommendations. These recommendations should provide guidance for professionals involved in the care of end-stage lung disease patients considered for transplantation. 相似文献
2.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
3.
《Revista de gastroenterologia de Mexico》2022,87(1):52-58
IntroductionThe sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12 weeks post-treatment a relevant undertaking.MethodsA retrospective review of the case records of 241 patients seen at 20 hospitals in Mexico was conducted to assess hepatitis C treatment with the SOF/VEL combination (n = 231) and the sofosbuvir/velpatasvir/ribavirin (SOF/VEL/RBV) combination (n = 10). The primary efficacy endpoint was the percentage of patients that achieved SVR at 12 weeks after the end of treatment.ResultsOverall SVR was 98.8% (95% CI 97.35-100%). Only three patients did not achieve SVR, two of whom had cirrhosis and a history of previous treatment with peg-IFN. Of the subgroups analyzed, all the patients with HIV coinfection, three patients with genotype 3, and the patients treated with the SOF/VEL/RBV combination achieved SVR. The subgroups with the lower success rates were patients that were treatment-experienced (96.8%) and patients with F1 fibrosis (95.5%). The most frequent adverse events were fatigue, headache, and insomnia. No serious adverse events were reported.ConclusionTreatments with SOF/VEL and SOF/VEL/RBV were highly safe and effective, results coinciding with those of other international real-world studies. 相似文献
4.
5.
《Vaccine》2022,40(31):4105-4115
The etiologic agents of visceral leishmaniasis are Leishmania infantum and Leishmania donovani. Despite the variety of drugs available to treat leishmaniasis, most lead to serious adverse effects, and resistance to these drugs has been reported. Currently, no leishmaniasis vaccine is available for humans. That is why the group developed transgenic L. infantum promastigote lines, which express toxic proteins after differentiation into amastigotes. That is why group developed the pFL-AMA plasmid and transfected it into L. Infantum promastigotes. This plasmid was expressed only in the amastigote form of the parasite. Sequences encoding toxic proteins (active bovine trypsin and egg avidin) were inserted in this plasmid, and the transfected parasites died after the differentiation process. In this study, two immunization protocols were performed in BALB/c mice: prime and prime-boost immunization prior to challenge with the wild-type L. infantum (WT). The parasite burdens in the spleen, liver, and bone marrow were evaluated to verify immunological protection. Histopathological analysis of the spleen and liver and the humoral immune response were also performed. The data showed that the parasite burden was reduced in prime-boosted mice in the spleen, liver, and bone marrow, indicating that mice immunized with two doses of the transfected parasites were satisfactorily protected. High levels of IgG, IgG1, and IgG2a antibodies were observed, as well as the presence of anti-inflammatory cytokine Interleukine-10 and pro-inflammatory cytokine Tumor Necrosis Factor-α (TNF-α) and Interferon-γ (IFN – γ) suggesting a Th1/Th2 mix response, in addition to the presence of multinucleated giant cells in the spleen and lymphocyte infiltration in the liver. Therefore, L. infantum transfected with a toxic plasmid is an excellent vaccine candidate against visceral leishmaniasis and the application of a boost before the challenge promotes greater protection against WT L. infantum infection. 相似文献
6.
DNA损伤应答(DNA damage response,DDR)缺陷是近年来乳腺癌治疗研究的热门靶点之一。DDR通路负责DNA损伤后的识别、信号转导和修复,其功能异常可导致细胞的凋亡或基因组不稳定性的增加。目前进入临床研究阶段的乳腺癌DDR靶向药物主要包括多聚腺苷二磷酸核糖聚合酶[poly (ADP-ribose) polymerase,PARP]抑制剂、ATM抑制剂、CHEK1抑制剂、ATR抑制剂及WEE1抑制剂等。主要从DDR缺陷的概念、以DDR作为靶点的基本原理、DDR各类靶向药物的临床研究现状及其在临床应用中的难点与挑战等方面展开综述。 相似文献
7.
8.
Robert J. Motzer MD David F. McDermott MD Bernard Escudier MD Mauricio Burotto MD Toni K. Choueiri MD Hans J. Hammers MD PhD Philippe Barthélémy MD PhD Elizabeth R. Plimack MD Camillo Porta MD Saby George MD Thomas Powles MD Frede Donskov MD PhD Howard Gurney MD Christian K. Kollmannsberger MD Marc-Oliver Grimm MD Carlos Barrios MD Yoshihiko Tomita MD PhD Daniel Castellano MD Viktor Grünwald MD PhD Brian I. Rini MD M. Brent McHenry PhD Chung-Wei Lee MD PhD Jennifer McCarthy MA Flavia Ejzykowicz PhD Nizar M. Tannir MD 《Cancer》2022,128(11):2085-2097
9.
10.